Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135355 | 1.00 | AKR1B1 (0.36) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20134941 | 0.86 | AKR1B1 (0.40) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20134939 | 0.86 | AKR1B1 (0.40) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20135221 | 0.86 | AKR1B1 (0.40) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20134752 | 0.79 | ADAM17 (0.45) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL4232196 | 0.79 | CYP2C9 (0.55) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20134833 | 0.75 | CYP2C9 (0.41) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20135641 | 0.72 | TSHR (0.39) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL11010656 | 0.72 | CYP2C9 (0.47) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT | |
| SCHEMBL20135629 | 0.71 | AKR1B1 (0.35) | AKR1B1ALDH1A1CYP2C9CACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | AKR1B1 2158/4885ALDH1A1 584/4885CYP2C9 139/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | AKR1B1 2142/4885ALDH1A1 610/4885CYP2C9 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.